Amn Healthcare SEC Filings

AMN Healthcare Services (AMN) filed its Q3 2025 report, showing revenue of $634.5 million, down from $687.5 million a year ago. Net income rose to $29.3 million from $7.0 million, with diluted EPS of $0.76 versus $0.18.

Year to date, revenue was $1,982.2 million versus $2,249.1 million, and the company reported a net loss of $88.0 million, primarily reflecting a non-cash goodwill impairment of $109.5 million and a $18.3 million long‑lived asset impairment recorded earlier in the year. Q3 included a $39.2 million gain on the sale of the Smart Square scheduling software, for which AMN received $65.3 million in cash and a $10.0 million 9.000% promissory note due January 1, 2027.

Operating cash flow reached $193.9 million for the nine months. Cash and cash equivalents were $52.6 million, and total stockholders’ equity was $644.4 million at September 30, 2025. Segment Q3 revenue: Nurse & Allied $361.5 million, Physician & Leadership $178.2 million, Technology & Workforce $94.8 million.

Subsequent events: On October 6, 2025, AMN issued $400.0 million of 6.500% senior notes due 2031 and amended its credit facility (maturity extended to October 6, 2030; revolving commitments set at $450.0 million; leverage covenant updated). On October 22, 2025, it redeemed the $500.0 million 2027 notes using note proceeds, revolver borrowings, and operating cash.

AMN Healthcare Services, Inc. furnished an update on its business by reporting results for the fiscal quarter ended September 30, 2025. The company provided the details in a press release attached as Exhibit 99.1.

The information related to these quarterly results is furnished under Item 2.02 and, as stated, is not deemed “filed” under Section 18 of the Exchange Act. AMN’s common stock trades on the NYSE under the symbol AMN.

AMN Healthcare Services (AMN): Schedule 13G/A filed by FMR LLC

FMR LLC and Abigail P. Johnson filed Amendment No. 1 to their Schedule 13G for AMN Healthcare Services. The filing reports beneficial ownership of 4,409.09 shares of common stock, representing 0.0% of the class as of 09/30/2025. FMR reports 2,154.00 shares with sole voting power and 4,409.09 shares with sole dispositive power, with 0 shared voting or dispositive power.

The filing indicates ownership of five percent or less of the class. It also states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control. One or more other persons may have the right to receive dividends or sale proceeds, with no single such interest exceeding five percent.

AMN Healthcare (AMN) insider transaction: On 10/15/2025, an officer (Chief Information and Digital) reported the vesting of 9,330 shares of common stock upon Restricted Stock Units (RSUs) settlement. The filer disposed of 3,339 shares at $20.69 to cover taxes. Following these transactions, the filer beneficially owned 38,699 shares directly. RSUs remaining after the event totaled 9,331.

The RSUs were granted on 10/15/2024 under the AMN Healthcare 2017 Equity Plan and vest in two tranches on the first and second anniversaries of the grant date, subject to credited service.

AMN Healthcare Services (AMN) reported an insider transaction by its Chief Legal Officer. On 10/15/2025, 4,976 shares of common stock were acquired upon the vesting of Restricted Stock Units (transaction code M).

On the same date, 1,212 shares were withheld for taxes at $20.69 per share (code F). Following these transactions, the officer directly beneficially owned 20,496 shares. The RSUs were granted on 10/15/2024 under the AMN Healthcare 2017 Equity Plan and vest in two annual tranches.

AMN Healthcare Services (AMN) completed a refinancing move as its subsidiary issued $400.0 million 6.500% Senior Notes due January 15, 2031, guaranteed on a senior unsecured basis by the parent and certain subsidiaries. Interest is payable semi-annually on January 15 and July 15, commencing July 15, 2026. The notes are callable at 103.250% in 2027, 101.625% in 2028, and 100% thereafter; before October 15, 2027, up to 40% may be redeemed with equity proceeds at 106.500%, or otherwise at par plus a make‑whole premium. A change of control triggers a 101% repurchase offer.

The company also amended its revolving credit facility to $450.0 million (from $750.0 million) and extended maturity to October 6, 2030, while updating leverage covenants (max 5.25x through March 31, 2027; 5.00x through June 30, 2028; 4.75x thereafter) and adding a pricing tier at Net Leverage ≥4.25x. AMN expects to draw about $100.0 million on the revolver and, together with note proceeds and cash, redeem all $500.0 million 2027 notes on October 22, 2025.

Whitney M. Laughlin, Chief Legal Officer of AMN Healthcare Services, reported on Form 4 that 483 restricted stock units (RSUs) vested on September 15, 2025, converting into 483 shares of AMN common stock. Of those shares, 118 were sold or withheld at $18.25 per share to satisfy tax withholding, leaving the reporting person with 16,732 shares beneficially owned after the transactions. The RSUs were originally granted under the AMN Healthcare 2017 Equity Plan on September 15, 2023 and vest in three annual tranches; the units have no expiration date. The report is a routine insider equity vesting and tax-withholding transaction rather than a discretionary open-market purchase or sale.